Sulfa drugs were the first systemic synthetic antibacterials — the drugs that proved bacterial infection could be cured by chemistry. Gerhard Domagk demonstrated the activity of Prontosil in December 1932, at IG Farben's laboratories in Elberfeld, and was awarded the 1939 Nobel Prize in Physiology or Medicine for it. A separate disaster — the 1937 Elixir Sulfanilamide poisoning in the United States — killed 107 people and led directly to the 1938 Federal Food, Drug, and Cosmetic Act, the foundation of modern American drug regulation.

Educational reference — not medical advice. This page describes what is generally known about a drug family. It cannot account for your history, your other medicines, or your circumstances. Decisions about your own treatment belong with your doctor or pharmacist.

Before sulfa

For most of medical history, bacterial infection was treated with whatever happened to be at hand: antiseptics on wounds, supportive care, the patient's own immune system. Bacterial pneumonia, puerperal sepsis after childbirth, and streptococcal skin infections were common causes of death. There was no specific cure. Salvarsan, an arsenical introduced for syphilis early in the 20th century, was the closest thing to a directed antibacterial — narrow, toxic, and limited in scope.

Prontosil

Through the early 1930s, Gerhard Domagk and colleagues screened azo compounds for antibacterial activity in mice at IG Farben's Elberfeld works — the former Bayer laboratories, absorbed into the conglomerate in 1925. This was industrial-scale systematic screening rather than serendipity: the programme had run since 1927, and by 1929 the laboratory could test around thirty compounds a week. The chemists Fritz Mietzsch and Josef Klarer made the compounds; Domagk tested them.

On 20 December 1932 he infected mice with a streptococcus at many times the lethal dose and treated half of them with Prontosil, a brick-red dye. The result was read on Christmas Eve: every untreated mouse was dead, every treated mouse alive and well. The work was not published until February 1935, more than two years later. Within a few years it had transformed the treatment of streptococcal sepsis worldwide.

Researchers at the Pasteur Institute — Jacques and Thérèse Tréfouël, Federico Nitti and Daniel Bovet — then showed something curious. Prontosil did nothing in a test tube; it worked only inside a living animal. The active agent was not the dye but a metabolite, sulfanilamide, released when the body cleaved the azo bond. That is also why earlier in-vitro screening had missed the entire drug class. Sulfanilamide had been synthesised by the Austrian chemist Paul Gelmo in 1908 as a dye intermediate; its patent had long since lapsed, so anyone could make it, cheaply. Within months, generic sulfanilamide preparations were everywhere — a development that broke the commercial monopoly Bayer had assumed but accelerated the spread of the cure. The mechanism — competitive inhibition of bacterial folate synthesis — would not be understood until the 1940s. How sulfa drugs work covers the science.

The Nobel Prize

The Nobel Committee awarded Domagk the Prize in Physiology or Medicine in 1939. Nazi Germany had forbidden German citizens from accepting Nobel Prizes following an earlier political dispute over the Peace Prize, and Domagk was briefly arrested when he attempted to communicate his acceptance. He received the medal and diploma after the war, in 1947. The cash had by then reverted to the Nobel Foundation and was not paid.

Wartime use and the antibiotic era

Sulfonamide powders were carried in the field kits of soldiers in the Second World War, where they reduced wound infection. The drugs treated streptococcal pneumonia, meningitis, and a wide range of skin and soft-tissue infections. They had real limits — toxicity, narrow efficacy in some bacterial species, and the rapid emergence of resistance — but they were the first chemical agents to make routine bacterial illness reliably curable. Penicillin became widely available later in the 1940s and gradually displaced sulfonamides for many indications, but the sulfa drugs were the prototype that proved the antibiotic concept.

The 1937 Elixir Sulfanilamide disaster

In 1937 the S. E. Massengill Company in Tennessee sold a liquid preparation of sulfanilamide flavoured with raspberry, intended for children who could not swallow tablets. The solvent was diethylene glycol, an industrial liquid that the manufacturer's chemists assumed would be safe because it had a sweet taste. Diethylene glycol is severely nephrotoxic. 107 people died, many of them children. The episode is among the worst mass medication poisonings in U.S. history. The company's chief chemist, Harold Watkins, later took his own life; the owner publicly denied any responsibility.

The Massengill product had been sold entirely legally. Under the law of the time, selling an untested, poisonous medicine was not itself an offence: the Food and Drug Administration could act only against misbranding. What gave the agency a foothold was a technicality. The word "elixir" implied an alcoholic solution, and this preparation contained no alcohol — so it was misbranded, and 25 seizures followed. Had the company called it a "solution," the FDA would have had no legal authority over it at all. Public outrage forced legislative reform. In 1938 Congress passed the Federal Food, Drug, and Cosmetic Act, which for the first time required that new drugs be shown to be safe before sale. The mechanism that today reviews every new prescription medicine in the United States traces directly to this episode.

Diethylene glycol poisoning still happens. Counterfeit medicines and improperly compounded liquid preparations have caused diethylene glycol mass poisonings in several countries since 1937, most recently in the 21st century. The mechanism that killed in 1937 has not been retired by chemistry alone — it has been retired only by regulation, where regulation holds.

The modern era

Sulfa drugs no longer dominate antibacterial therapy. Resistance, the rise of penicillins and cephalosporins, and a better understanding of allergy have pushed them to specific roles — uncomplicated urinary tract infection, Pneumocystis jirovecii pneumonia prophylaxis and treatment, Stenotrophomonas infections, and others described on the sulfa antibiotics page. The non-antibiotic sulfonamides — furosemide, HCTZ, celecoxib, sulfonylureas, acetazolamide — emerged later as separate stories, sharing only the chemical group with the original sulfanilamide.

The historical assumption that any "sulfa allergy" precluded all sulfonamides was a product of the era when the antibiotics dominated and the chemistry was less well understood. Modern cross-reactivity data support a more limited reading.

A short history of sulfa drugs.